lu tian

Stanford University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Karen Ho

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Erik van Zwet

Associate Professor

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

Maria Montez-Rath

Stanford University School of Medicine

UNITED STATES

View details

Hajime Uno

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES

View details

W. Ray Kim

Professor and Chief

Stanford University

UNITED STATES

View details

Jennifer Frankovich

Clinical Professor of Pediatrics and Pediatric Rheumatology

Stanford University Medical Center

UNITED STATES

View details

Ruben van Eijk

Assistent professor

UMC Utrecht

NETHERLANDS

View details

Satoshi Hattori

Osaka University

JAPAN

View details

Kit Roes

Professor of Biostatistics

Radboudumc

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

lu tian

Research Interests

Explore related searches

Contact this professor

Articles (26)

Duration of Supervised Exercise Necessary for Meaningful Improvement in Peripheral Artery Disease

Comment on “Average Hazard as Harmonic Mean” by Chiba (2025)

A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time‐To‐Event Outcomes Using Average Hazard With Survival Weight

Dynamic Decision Making With Individualized Variable Selection

Model‐Free Approach to Evaluate a Censored Intermediate Outcome as a Surrogate for Overall Survival

On the two-step hybrid design for augmenting randomized trials using real-world data

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties

Assessing the harm and benefit of cancer therapies with an overall survival endpoint in comparative clinical studies

A General Framework to Assess Complex Heterogeneity in the Strength of a Surrogate Marker

RMST for Interval‐Censored Data in Oncology Clinical Trials

Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD

Assessing heterogeneity in surrogacy using censored data

Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD

Regression models for average hazard

Evaluating a shrinkage estimator for the treatment effect in clinical trials

A rank-based approach to evaluate a surrogate marker in a small sample setting

On assessing survival benefit of immunotherapy using long‐term restricted mean survival time

Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study

Exact inference for disease prevalence based on a test with unknown specificity and sensitivity

Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer

Evaluation of C4 Gene Copy Number in Pediatric Acute Neuropsychiatric Syndrome

Robust approach to combining multiple markers to improve surrogacy

Testing for heterogeneity in the utility of a surrogate marker

Causal inference for longitudinal data based on historical controls

A seasonality‐adjusted sequential test for vaccine safety surveillance

Using a surrogate with heterogeneous utility to test for a treatment effect

Collaborators (9)

Karen Ho

Erik van Zwet

Maria Montez-Rath

Hajime Uno

W. Ray Kim

Jennifer Frankovich

Ruben van Eijk

Satoshi Hattori

Kit Roes

Make your next move.